Oncolytic HSV-1 Expressing IL-12, IL-15/IL-15-receptor Alpha and PD-L1 Blocking Peptide VG161 clinical trials
Also written VG161.
How each study uses Oncolytic HSV-1 Expressing IL-12, IL-15/IL-15-receptor Alpha and PD-L1 Blocking Peptide VG161 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Oncolytic HSV-1 Expressing IL-12, IL-15/IL-15-receptor Alpha and PD-L1 Blocking Peptide VG161 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
CNBG-Virogin Biotech (Shanghai) Ltd. (6) · Ding-Wei Ye (1) · Virogin Biotech Canada Ltd (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Oncolytic HSV-1 Expressing IL-12, IL-15/IL-15-receptor Alpha and PD-L1 Blocking Peptide VG161 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Clinical Study of VG161 in Advanced Intrahepatic CholangiocarcinomaRecruitingPhase 2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06746480Written as Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))How we know
- Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue SarcomaRecruitingPhase 2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06126510Written as Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)How we know
- Clinical Study of VG161 in Subjects with Advanced Primary Liver CancerRecruitingPhase 1CNBG-Virogin Biotech (Shanghai) Ltd.NCT04806464Written as Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))How we know
- An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic CholangiocarcinomaRecruitingPhase 2Virogin Biotech Canada LtdNCT05223816Written as VG161How we know
- Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular CarcinomaNot yet recruitingPhase 1/2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06124001Written as Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))How we know
- Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerRecruitingPhase 1/2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06008925Written as Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))How we know
- A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder CancerCompletedPhase 1/2Ding-Wei YeNCT07505615Written as VG161 via Intravesical InstillationHow we know
- Clinical Study of VG161 in Subjects With Advanced Malignant Solid TumorsStatus unknownPhase 1CNBG-Virogin Biotech (Shanghai) Ltd.NCT04758897Written as Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))How we know